a Carboplatin+oxaliplatin: 2 patients;
Cisplatin+nedaplatin/lobaplatin/carboplatin: 3 patients; Nedaplatin+lobaplatin: 1 patient.
Table S2. The association of baseline factors with post-recurrence survival in patients treated with PARPi monotherapy and platinum-based chemotherapy.